AIT-082; A DRUG FOR TREATMENT OF ALZHEIMER'S DISEASE

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$478,811.00
Award Year:
1993
Program:
SBIR
Phase:
Phase II
Contract:
n/a
Agency Tracking Number:
16260
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Advanced Immunotherapeutics
2691 Richter Avenue, Suite 105, Irvine, CA, 92714
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Glasky, Alvin J
Principal Investigator
(714) 756-2230
Business Contact:
1 R43 AG09911-01
() -
Research Institution:
n/a
Abstract
WE WILL DEVELOP AIT-082 FOR THE TREATMENT OF DEMENTIA DUE TO ALZHEIMER'S DISEASE, STROKE OR AGING. IN PHASE I, WE PLAN TO COMPLETE THE PRECLINICAL STUDIES NEEDED TO SUBMIT AN INVESTIGATION- AL NEW DRUG (IND) EXEMPTION APPLICATION TO THE FOOD AND DRUG ADMINISTRATION (FDA). SPECIFICALLY, WE WILL: (1) DETERMINE THE PRECLINICAL PHARMACODYNAMICS/ PHARMACOKINETICS OF AIT-082, (2) CONDUCT PRECLINICAL TOXICOLOGICAL TESTING, AND (3) CONDUCT ADDITIONAL PRECLINICAL STUDIES ON THE MECHANISM OF ACTION OF AIT- 082. THE AIM OF PHASE II WILL BE TO FILE AN IND APPLICATION AND TO ESTABLISH THE CLINICAL SAFETY AND EFFICACY OF AIT-082.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government